(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 12.81% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 123.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Alpha Teknova's revenue in 2025 is $38,250,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2025 to be $2,209,243,085, with the lowest TKNO revenue forecast at $2,107,278,020, and the highest TKNO revenue forecast at $2,295,015,585. On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,545,118,576, with the lowest TKNO revenue forecast at $2,409,111,715, and the highest TKNO revenue forecast at $2,693,416,824.
In 2027, TKNO is forecast to generate $2,955,704,319 in revenue, with the lowest revenue forecast at $2,804,413,386 and the highest revenue forecast at $3,080,595,492.